Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.

The de-Glycosylated vitamin D binding protein is a powerful Macrophage Activating Factor (GcMAF) that shows multiple biological effects that could be exploited in the immunotherapy of tumours, viral infections and autism. Here we report the observation of a series of clinical cases describing the results obtained administering highly purified GcMAF to patients with diverse types of chronic diseases. These are heterogeneous and refer to patients with different types of diseases at different stages. In some cases, patients underwent other complementary treatments such as stem cell infusion or administration of supplements. In patients harbouring tumours, GcMAF treatment was initiated at late stages of tumour progression. Therefore, since this is an open-label, non-controlled, retrospective analysis, caution must be employed when ascribing cause and effect to any treatment outcome. However, the response to GcMAF was robust and certain trends emerge evident. In all cases (n = 7), GcMAF subcutaneous injections were associated with improvement of clinical conditions. No adverse side effects were reported. The observation reported here confirm and extend the results previously presented by several Authors and open the way to further trials aimed at assessing the precise role and indications for GcMAF in the immunotherapy of chronic diseases.